From Micromold Accuracy to Drug Delivery: Why Geometric Fidelity Does Not Establish Transdermal Performance

Dimensional conformity and run-to-run reproducibility are distinct manufacturing attributes: a process can consistently reproduce a geometry that deviates from its design. Neither attribute alone establishes skin insertion, drug release, tissue deposition, receptor permeation, delivered dose, or clinical exposure. We examine the claim boundaries of these measurements using the experimental sequence reported by Antonara et al. (2025), who employed an LCD-printed 3Dresyn Bioflex D60 MB resin mold to cast ropinirole-loaded poly(vinyl alcohol) microneedles. Their results include geometry-specific dimensional measurements, Parafilm insertion screening and ex vivo permeation through porcine skin. We organize a stage-resolved evidence map, adapt established compartmental mass accounting to this manufacturing route, and use bounded conditional fractions to examine what can and cannot be inferred across fabrication, insertion and transport. Four completely hypothetical parameter sets demonstrate non-identifiability: equal geometric fidelity and initial loading can accompany different receptor amounts, while the same receptor amount may arise from distinct upstream losses. A prospective qualification design separates mold accuracy, demolding, application mechanics, drug recovery, tissue retention and receptor permeation. The contribution is an auditable reporting framework, not a new mass-balance principle, an empirical reanalysis or a validated clinical dose model. Supplier materials, printed tools and final drug-delivery systems must be evaluated in their respective roles, including possible process-derived transfer from mold to product.